作者:Amy Capes、Stephen Patterson、Susan Wyllie、Irene Hallyburton、Iain T. Collie、Andrew J. McCarroll、Malcolm F.G. Stevens、Julie A. Frearson、Paul G. Wyatt、Alan H. Fairlamb、Ian H. Gilbert
DOI:10.1016/j.bmc.2011.12.018
日期:2012.2
Quinols have been developed as a class of potential anti-cancer compounds. They are thought to act as double Michael acceptors, forming two covalent bonds to their target protein(s). Quinols have also been shown to have activity against the parasite Trypanosoma brucei, the causative organism of human African trypanosomiasis, but they demonstrated little selectivity over mammalian MRC5 cells in a counter-screen
喹啉已被开发为一类潜在的抗癌化合物。它们被认为充当双迈克尔受体,与它们的靶蛋白形成两个共价键。喹诺酮类化合物也被证明对寄生虫布氏锥虫(人类非洲锥虫病的致病微生物)具有活性,但在反筛选中它们对哺乳动物 MRC5 细胞几乎没有选择性。在本文中,我们报告了针对T. brucei的喹啉的进一步例子的筛选. 我们能够推导出 SAR,但这些化合物对 MRC5 细胞几乎没有选择性。在提高选择性的一种方法中,我们将三聚氰胺和苯甲脒基序连接到喹啉上,因为已知这些基元通过转运蛋白选择性地集中在寄生虫中。一般来说,这些含有转运蛋白基序的类似物显示出更高的选择性。然而,它们也显示出对布氏锥虫的效力水平降低。